文章核心观点 - 生物制药公司Agenus的一项针对结直肠癌的二期临床试验未能达到预期目标,FDA建议公司不要申请加速审批[1][2][3] - FDA的建议是因为试验结果的客观反应率未必能转化为生存获益,这将延缓该结直肠癌治疗候选药物的开发和审评[3] - 公司首席医疗官表示,尽管如此,公司仍将寻求所有可能的途径让该疗法惠及患者,包括在美国寻找合作伙伴以成功进行三期试验[4] 公司相关 - Agenus是一家临床阶段的生物制药公司[1] - 公司正在开发一种名为botensilimab和balstilimab的结直肠癌治疗方案[1][2] - 公司与FDA进行了二期临床试验的终点会议,FDA建议公司不要申请加速审批[2] 股票相关 - 由于FDA不建议加速审批,Agenus股价大跌54.5%,成交量大幅增加至5.2百万股,远高于日均763,000股[5] - 投资者对此反应强烈,对公司未来发展前景表示担忧[5]

Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst. Small-cap and mid-cap stocks tend to be interest rate sensitive. The core reason is that many of these companies are dependent on debt instruments to meet their long-term financial obligations. Although the Federal Reserve is wobbling on a possible rate reduction this year due to sticky inflation, the central bank is widely expected to slash rates no ...

Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman & Chief Executive Officer Steven O’Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Christine Klaskin - Vice President of Finance & Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainright Mayank Mamtani - B. Riley Securities Matthew Phipps - William Blair Operator Thank you for sta ...

Agenus (AGEN) came out with a quarterly loss of $3.04 per share versus the Zacks Consensus Estimate of a loss of $3.58. This compares to loss of $4.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15.08%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.40 per share when it actually produced a loss of $2.60, delivering a surprise of -550%. Over the last four quarters, the company has su ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No .) 3 Forbes Road Lexington, Massachusetts 02421 (Address of Principal Executive O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of (I.R.S. Emplo ...

This small-cap biotech stock is surging. Time to buy? Last Friday, Agenus (AGEN 40.84%), an immuno-oncology player, saw its shares soar by a staggering 40.8%. This remarkable rally occurred seemingly without a clear catalyst. The company is set to announce its first- quarter earnings for 2024 before the market opens on Tuesday, May 7. However, there's no certainty that the company will release any information that justifies this significant surge in its shares. So, what's causing all the excitement? Investo ...

Loading... Loading... The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of ...

Agenus (AGEN) shares rallied 6.8% in the last trading session to close at $5.31. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 55.8% loss over the past four weeks. Earlier this month, the company announced updated data from its phase I study evaluating the BOT/BAL combination therapy in patients with metastatic colorectal cancer that is not microsatellite instability-high (MSS) or deficient mismatch repair ...

Agenus股价表现 - Agenus的股价自去年六月的高点以来已经下跌了约75%[1] - Agenus的股价目前低于1美元，如果接近华尔街的预期，可能会带来巨大回报[3] Agenus业务展望 - Agenus是一家临床阶段的癌症药物开发公司，尽管没有任何已批准销售的产品，但仍有潜力[5] - Agenus与大型制药公司合作，开发了一个新一代的CTLA-4阻断抗体botensilimab[8] Botensilimab研究进展 - Botensilimab在一项针对晚期结肠癌患者的单臂研究中，对17名患者的肿瘤产生了缩小的效果[9] - Botensilimab目前正在进行更大规模的第2阶段研究，预计在2024年下半年公布结果[9] Agenus未来展望 - Agenus的市值目前只有2.11亿美元，成功的任何项目都有可能推动股价飙升[10] - Agenus的现金储备较低，可能需要在2025年通过发行新股筹集资金[14] 投资建议 - 投资者应该谨慎考虑购买Agenus股票，因为其候选药物的成功并不是确定的[11] - 投资者应该保持距离，观察Agenus的故事发展，而不是立即购买股票[15]